Canada Gives Kids First Type 1 Diabetes Delaying Drug

For the first time in Canada, two children received a medication that can delay type 1 diabetes before they even need insulin.

The kids were treated at BC Children's Hospital with Tzield, a drug approved by Health Canada in 2025 for children age 8 and up. Clinical studies show it delays insulin-dependent diabetes by a median of two years in people who show early signs of the disease but don't yet need daily injections.

Those two years matter deeply to families. Fewer medical emergencies, more time to prepare, and more normal childhood moments before insulin becomes part of daily life.

Tzield works by targeting the immune system before it fully destroys the insulin-producing cells in the pancreas. The drug is given through an infusion over 14 days to people identified through early screening who have stage 2 type 1 diabetes.

A small number of Canadian adults already received Tzield since approval. What makes this news special is that children are now benefiting from the first disease-modifying therapy for type 1 diabetes, not just another way to manage symptoms.

Getting screened is the key to accessing this treatment. Family members of people with type 1 diabetes can get tested through programs like TrialNet and FEDERATE-Can. People without a family history can discuss screening options with their healthcare providers through resources like uncovert1d.ca.

The catch? Most newly diagnosed people have no family history, which means over 85% of cases could be missed through family screening alone. Broader screening programs will be essential for more children to benefit.

The Ripple Effect

This Canadian first signals a fundamental change in how we approach type 1 diabetes. For decades, families waited for symptoms to appear, then rushed to emergency rooms when children showed signs of life-threatening diabetic ketoacidosis.

Now there's a window to act earlier. Screen, detect, and potentially delay, giving families precious time and reducing trauma.

The US FDA recently approved Tzield for children as young as one year old with stage 2 type 1 diabetes. Canada currently limits use to age 8 and above, but the trend points toward earlier intervention becoming standard care.

Access remains limited. Canada's Drug Agency recommended against reimbursing Tzield in January, meaning most families would face steep out-of-pocket costs. The two children at BC Children's received the medication through a compassionate use program provided by manufacturer Sanofi.

Advocacy groups like Breakthrough T1D Canada continue pushing for better screening access and coverage for disease-modifying treatments. Every child who gets two more years without insulin injections proves the approach works.

This is what progress looks like in real time: small steps, real families, and a disease that's finally meeting its match.